Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Telmisartan/HCTZ FDC vs Monocomponents
NCT02262624Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2005
- Primary completion
- Feb 2005
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of telmisartan and hydrochlorothiazide in hypertension (HTN) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve from 0 to the last quantifiable data point up to 72 hours and Maximum measured concentration of the analyte in plasma up to 72 hours. Started Feb 2005; status: completed.
02
Drugs
telmisartanhydrochlorothiazide
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT02262624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02262624.